Literature DB >> 15035887

Inflammation as cause for scar cancers of the lung.

C Murray Ardies1.   

Abstract

The molecular and cellular basis of inflammation has become a topic of great interest of late because of the association between mechanisms of inflammation and risk for cancer. Inflammatory-mediated events, such as the production of reactive oxygen species (ROS), the activation of growth factors (for wound repair), and the altering of signal-transduction processes to activate cell-proliferation (to replace necrotic/apoptotic tissue cells), events that also can occur independently of inflammation, are all considered to be components of risk for a variety of cancers. Using scar cancer of the lung as an example, mechanisms of inflammation associated with recurring infections with Mycobacterium tuberculosis are discussed in the context that they may, in fact, be the major or sole cause of a cancer. Production of ROS, prostaglandins, leukotrienes, and cytokines in pulmonary tissues is greatly enhanced due to a cell-mediated immune response against macrophages infected with M. tuberculosis. These responses lead to the extensive fibrosis associated with recurring infections, possibly leading to decreased clearance of lymph and lymph-associated particles from the infected region. They also will enhance rates of cell division by inhibiting synthesis of P21, leading to enhanced progression from G0 arrest to G1 phase, from G1 to Sphase, and from G2 to M phase of the cell cycle. By increasing rates of oxidative DNA damage and inhibiting apoptosis by enhancing synthesis of BCL-2, mutagenesis of progeny cells is enhanced, and these effects coupled with enhanced angiogenesis stimulated by COX-2 products lead to an environment that is highly conducive to tumorigenesis. Based on the evidence, it appears that but for an inflammatory response to recurring infections, some cases of scar cancer would not exist. By making appropriate lifestyle and dietary changes, a variety of anti-inflammatory effects can be produced, which should attenuate inflammation-induced risk for cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15035887     DOI: 10.1177/1534735403256332

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  27 in total

1.  CT features of lung scar cancer.

Authors:  Feng Gao; Xiaojun Ge; Ming Li; Xiangpeng Zheng; Li Xiao; Guozhen Zhang; Yanqing Hua
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

2.  A new role for microRNAs, as ligands of Toll-like receptors.

Authors:  Muller Fabbri; Alessio Paone; Federica Calore; Roberta Galli; Carlo M Croce
Journal:  RNA Biol       Date:  2013-01-07       Impact factor: 4.652

3.  Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.

Authors:  Julien Cherfils-Vicini; Sophia Platonova; Mélanie Gillard; Ludivine Laurans; Pierre Validire; Rafaele Caliandro; Pierre Magdeleinat; Fathia Mami-Chouaib; Marie-Caroline Dieu-Nosjean; Wolf-Herman Fridman; Diane Damotte; Catherine Sautès-Fridman; Isabelle Cremer
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

4.  Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease.

Authors:  D D Sin; L Wu; J A Anderson; N R Anthonisen; A S Buist; P S Burge; P M Calverley; J E Connett; B Lindmark; R A Pauwels; D S Postma; J B Soriano; W Szafranski; J Vestbo
Journal:  Thorax       Date:  2005-10-14       Impact factor: 9.139

5.  Macrophages are needed in the progression of tuberculosis into lung cancer.

Authors:  Jin Li; Yanyu Pan; Baohua Zhang; Qihuang Chen
Journal:  Tumour Biol       Date:  2015-03-13

Review 6.  Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells.

Authors:  Katrin Eurich; Mayuko Segawa; Satoko Toei-Shimizu; Emiko Mizoguchi
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

7.  Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  Ying-Ying Yu; Paul F Pinsky; Neil E Caporaso; Nilanjan Chatterjee; Mona Baumgarten; Patricia Langenberg; Jon P Furuno; Qing Lan; Eric A Engels
Journal:  Arch Intern Med       Date:  2008-11-24

8.  Ectoenzymes and cholinesterase activity and biomarkers of oxidative stress in patients with lung cancer.

Authors:  Daniela Zanini; Roberta Schmatz; Luana Paula Pelinson; Victor Camera Pimentel; Pauline da Costa; Andréia Machado Cardoso; Caroline Curry Martins; Christina Chitolina Schetinger; Jucimara Baldissareli; Maria do Carmo Araújo; Liliane Oliveira; Juarez Chiesa; Vera Maria Morsch; Daniela Bitencourt Rosa Leal; Maria Rosa Chitolina Schetinger
Journal:  Mol Cell Biochem       Date:  2012-11-18       Impact factor: 3.396

9.  Increased risk of secondary lung cancer in patients with tuberculosis: A nationwide, population-based cohort study.

Authors:  Li-Ju Ho; Hung-Yi Yang; Chi-Hsiang Chung; Wei-Chin Chang; Sung-Sen Yang; Chien-An Sun; Wu-Chien Chien; Ruei-Yu Su
Journal:  PLoS One       Date:  2021-05-07       Impact factor: 3.240

10.  Pulmonary tuberculosis and lung cancer risk in current smokers: the Seoul Male Cancer Cohort Study.

Authors:  Jong-Myon Bae; Zhong-Min Li; Myung-Hee Shin; Dong-Hyun Kim; Moo-Song Lee; Yoon-Ok Ahn
Journal:  J Korean Med Sci       Date:  2013-06-03       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.